Business Wire

MA-WATERS-CORPORATION

12.1.2022 15:12:07 CET | Business Wire | Press release

Share
Waters Accelerates Quantitative Mass Spectrometry With New Application on waters_connect Informatics Platform

Waters Corporation (NYSE:WAT) today announced it is expanding its waters_connect™ informatics software platform to support customers analyzing food and environmental samples with Waters’ tandem quadrupole mass spectrometers. The new MS Quan ™ application for waters_connect allows laboratories screening large numbers of samples, or those who may be quantifying hundreds of small molecule components and contaminants in a single run, a more efficient means of processing and reviewing data and identifying batch-to-batch variations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005625/en/

For laboratories using Waters™ Xevo™ mass spectrometers, the MS Quan app quickly and accurately converts measurement data on compounds into meaningful results in a traceable, compliant, and secure manner. Featuring a web-based user interface, the MS Quan app includes an Exception Focused Review (XFR) feature that can help cut data review time by up to 50% by allowing users to focus on only those results that fall outside the user-determined ruleset.

“The waters_connect platform provides a backbone for the connected lab of the future where data is no longer siloed but can be securely shared among a community of connected scientists using apps that talk to each other,” said Jon Pratt, Senior Vice President, Waters Corporation. “MS Quan is a great example of the new applications and quality improvements we are bringing to our customers via waters_connect and its platform architecture designed for data integrity, compliance, security and accessibility.”

Several scientists from Primoris (Zwijnaarde, Belgium), a global contract laboratory, participated in the beta testing of the MS Quan software application. Primoris measures pesticide residues and contaminants in food and animal feed as well as analyzing food additives, supplements, and essential oils.

“We’ve used MassLynx and TargetLynx from Waters for a very long time so we knew from the beginning the potential that this new app will offer," said Janne Dombrecht, Analysis Lead, Primoris Belgium. “The final product is exactly what we were looking for. Our close relationship with Waters and being able to test this product to make sure it is optimal for our methods has been a win-win situation. We’re excited to roll it out across Primoris!”

The waters_connect for quantitation workflow and MS Quan app are now available worldwide as an upgrade for select Waters’ tandem quadrupole mass spectrometers.i

Additional Resources

About Waters Corporation (www.waters.com )

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, MS Quan, Xevo, MassLynx, TargetLynx, and waters_connect are trademarks of Waters Corporation. Primoris is a trademark of Primoris Belgium.

____________________________
i At this time the MS Quan app is for small molecule quantification studies and compatible with Waters Xevo TQ-XS, a Waters Xevo TQ-S micro and Waters TQ-S cronos tandem quadrupole mass spectrometers with either an ACQUITY I-Class, H-Class System or ACQUITY Premier System front-end. Additionally, waters_connect software is currently available as an “on-premise” only workstation product.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye